Suchergebnisse - "Hatemi, Gülen"

PubPharm (14)

1

COVID-19 Among Patients With Inflammatory Rheumatic Diseases

enthalten in: Frontiers in immunology | 2021

von Esatoglu, S. | Tascilar, K. | Babaoğlu, H. | +52

2

Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey

enthalten in: Rheumatology international | 2020

von Ayan, G. | Esatoglu, S. | Hatemi, G. | +1

3

2018 Update of the EULAR recommendations for the management of large vessel vasculitis

enthalten in: Annals of the rheumatic diseases | 2020

von Hellmich, B. | Agueda, A. | Monti, S. | +23

4

Immunogenicity of Infliximab Among Patients With Behçet Syndrome : A Controlled Study

enthalten in: Frontiers in immunology | 2020

von Esatoglu, S. | Akkoc-Mustafayev, F. | Ozguler, Y. | +8

5

Tapering tumour necrosis factor inhibitors in rheumatoid arthritis : a retrospective study

enthalten in: Clinical and experimental rheumatology | 2019

von Hacioglu, A. | Hatemi, G. | Esatoglu, S. | +1

6

Assessing the possible association of anti-TNF use with new malignancies : A neglected methodological consideration

enthalten in: Pharmacoepidemiology and drug safety | 2018

von Ozguler, Y. | Yazici, Y. | Hatemi, G. | +2

7

Biomarkers in vasculitis

enthalten in: Current opinion in rheumatology | 2018

von Hatemi, G. | Esatoglu, S. | Yazici, Y.

8

Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy

enthalten in: Rheumatology international | 2016

von Ozguler, Y. | Hatemi, G. | Ugurlu, S. | +6

9

Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration : Comment on the Article by Singh et al

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2016

von Yazici, H. | Ozguler, Y. | Hatemi, G. | +1

CommentOn: Arthritis Rheumatol. 2016 Jan;68(1):1-26. - PMID 26545940

10

Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration : Comment on the Article by Singh et al

enthalten in: Arthritis care & research | 2016

von Yazici, H. | Ozguler, Y. | Hatemi, G. | +1

CommentOn: Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. - PMID 26545825